Use Case

Clinical Trial Decisions

Gain insights into your clinical trial data to inform phase transition.

Drugs are not equally effective across all patients. K Pro’s specialized AI skills work together to understand treatment response and identify biomarkers that define the patients most likely to benefit.

Book a Demo

Solving actual pharma R&D challenges in minutes

Challenge

Getting answers from clinical trial data

We have data from our Phase II study. Before we lock the Phase III design, I need to understand the baseline characteristics of our cohort, identify imbalances between response groups, and surface any genomic signal we might have missed.

Clinical Trial Director, Oncology

In MY CLINICAL TRIAL DATA, what is the distribution of age, ethnicity and mutations in the trial population?

Are there any significant baseline imbalances between response groups in MY CLINICAL TRIAL DATA?

What genes are differentially expressed between treatment response groups (complete and partial response) in MY CLINICAL TRIAL DATA?

$Is the lack of Chr17-LOH associated with refractoriness to platinum in MY CLINICAL TRIAL DATA?$

Impact

Unlock clinical trial insights in minutes

Understand the baseline characteristics of your trial cohort, identify imbalances between response groups, and surface the genomic signals driving sensitivity or resistance. Gain the confidence to define your enrichment strategy and advance your next trial phase based on your own data.